Arcellx (ACLX) Return on Capital Employed (2022 - 2025)
Arcellx's (ACLX) quarterly Return on Capital Employed came in at 48.14% in Q4 2025, down 2568.0% year-on-year from 1.95% in Q4 2024, and down 3.02% quarter-over-quarter from 46.72% in Q3 2025.
Arcellx (ACLX) Return on Capital Employed (2022 - 2025) Analysis & Trends
Arcellx's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 48.14% for Q4 2025.
- On a quarterly basis, Return on Capital Employed fell 2568.0% year-over-year to 48.14% in Q4 2025; TTM through Dec 2025 was 48.14%, a 2568.0% decrease from a year earlier, with the FY2025 full-year figure at 45.73%, down 2433.0% from the prior year.
- Return on Capital Employed declined to 48.14% in Q4 2025 per ACLX's latest filing, from 46.72% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 10.83% in Q1 2024 and bottomed at 71.13% in Q4 2022.
- The 4-year median for Return on Capital Employed is 37.56% (2023), against an average of 36.64%.
- Across the five-year window, Return on Capital Employed soared 5619 bps in 2023 and sank 3539 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 71.13% in 2022, then soared by 79 bps to 14.94% in 2023, then plunged by 50 bps to 22.45% in 2024, then slumped by 114 bps to 48.14% in 2025.
- Per Business Quant, the three latest ACLX Return on Capital Employed figures stand at 48.14% (Q4 2025), 46.72% (Q3 2025), and 41.9% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -48.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -48.14% |
| Sep 30, 2025 | -46.72% |
| Jun 30, 2025 | -41.90% |
| Mar 31, 2025 | -33.61% |
| Dec 31, 2024 | -22.45% |
| Sep 30, 2024 | -11.33% |
| Jun 30, 2024 | -12.06% |
| Mar 31, 2024 | -10.83% |
| Dec 31, 2023 | -14.94% |
| Sep 30, 2023 | -32.51% |
| Jun 30, 2023 | -41.51% |
| Mar 31, 2023 | -64.71% |
| Dec 31, 2022 | -71.13% |
| Sep 30, 2022 | -55.25% |
| Jun 30, 2022 | -33.16% |
| Mar 31, 2022 | -46.02% |